Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study. - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 sites20 target enrollmentJune 23, 2006

Overview

No summary available.

Registry

who.int

Start Date

June 23, 2006

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

•Exudative age related macular degeneration age 60 and visual acuity between FC finger count and 0,5 decimal ETDRS table . The location of choroidal neovascularization CNV should be subfoveal either classic 4 disc diameter, minimally classic CNV or occult CNV, as well as RAP lesions more than II stage, lesions with large haemorrhagic component, large pigment epithelial detachments PED . Are also included in the study patients that are not eligible for photodinamic therapy PDT because they do not accomplish the PDT treatment criteria low vision, presence of disciform scar , or because they refuse PDT or other treatment for the cure of their pathology.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

•Patients with exudative age related macular degeneration with classic CNV 4 disc diameter. Patients with exudative maculopathy CNV not related to age related macular degeneration such as pathologic myopia, inflammation, angioid streaks. Patients with media opacity in which is not possible to evaluate the details the fundus of the eye